Metformin + Rapamycin + D+Q Senolytics Interaction

⚠️ RESEARCH-BASED INTERACTION DATA — NOT COMPREHENSIVE.

Interaction Type: synergistic | Evidence Level: theoretical

The 'longevity trifecta' targets three hallmarks of aging: mTOR hyperactivation (rapamycin), metabolic dysfunction (metformin), and senescent cell accumulation (D+Q senolytics).

Mechanism of Interaction

Each component addresses a distinct aging mechanism: Rapamycin inhibits mTORC1 → promotes autophagy, reduces inflammation. Metformin activates AMPK → improves metabolic health, mimics caloric restriction. D+Q clears senescent cells → reduces SASP inflammation, restores tissue function. Together, they create a multi-target approach to the interconnected hallmarks of aging.

Clinical Relevance

No clinical trials test all three together. Each has individual clinical evidence for aging-related outcomes. Some longevity physicians prescribe combinations. The TAME trial (metformin), PEARL (rapamycin), and AFFIRM (fisetin) each study individual components.

Recommendations

• This is a research-level combination — not standard medical practice
• Stagger medications to minimize combined side effects
• Comprehensive baseline labs required (metabolic panel, CBC, lipids, inflammatory markers)
• Regular monitoring by a physician experienced in longevity medicine is essential

Relevant Conditions

• Comprehensive longevity protocols
• Age-related disease prevention